[
    [
        {
            "time": "2018-04-17",
            "original_text": "Xultophy® approved in Canada for the treatment of adults with type 2 diabetes",
            "features": {
                "keywords": [
                    "Xultophy",
                    "approved",
                    "Canada",
                    "type 2 diabetes"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Xultophy® approved in Canada for the treatment of adults with type 2 diabetes",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-17",
            "original_text": "Analysts’ Recommendations for Novartis on April 17",
            "features": {
                "keywords": [
                    "Analysts",
                    "Recommendations",
                    "Novartis"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Analysts’ Recommendations for Novartis on April 17",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-17",
            "original_text": "Novartis’s 1Q18 Estimates: Expectations for Alcon",
            "features": {
                "keywords": [
                    "Novartis",
                    "1Q18",
                    "Estimates",
                    "Alcon"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "ophthalmology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novartis’s 1Q18 Estimates: Expectations for Alcon",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]